China has achieved a major milestone in neurotechnology with the successful implantation of the world’s first commercially approved brain-computer interface (BCI) chip in a patient with spinal cord injury. The landmark procedure was carried out on July 13 by a multidisciplinary team at Huashan Hospital, affiliated with Fudan University in Shanghai, using the NEO Brain-Computer Interface System developed by Chinese medical device company NeuraClear Medical Technology.

Restoring Hand Function a Decade After Injury

The recipient, who lost hand function following a traffic accident nearly 10 years ago, underwent the procedure as part of an effort to restore motor function through advanced brain-machine communication. The implanted system captures neural signals from the brain and translates them into commands that support hand movement and rehabilitation, offering new hope for patients living with paralysis caused by spinal cord injuries.

How the NEO BCI System Is Different

Unlike conventional invasive brain-computer interfaces that penetrate brain tissue, the NEO BCI system uses an extradural design, placing its electrodes on the surface of the brain without entering the cerebral cortex. According to the research team, this minimally invasive approach enabled stable, high-quality neural signal acquisition while potentially reducing the surgical risks associated with penetrating implants. The patient’s postoperative recovery has been reported as stable, with normal vital signs and no immediate complications.

A Fast-Growing Field in Neuroscience

Brain-computer interfaces are widely regarded as one of the fastest-evolving fields in neuroscience and rehabilitation medicine. Globally, researchers are exploring BCI technology to restore movement, speech, and communication in patients affected by spinal cord injuries, stroke, amyotrophic lateral sclerosis (ALS), and other neurological disorders. Industry analysts estimate the global brain-computer interface market could surpass US$6 billion by 2030, driven by rapid advances in neuroengineering, artificial intelligence, and implantable medical devices.

What This Means for the Future of Neurorehabilitation

The successful commercial implantation marks a significant step towards the clinical adoption of brain-computer interface technology in China. Researchers at Fudan University and Huashan Hospital believe the achievement could accelerate the development of next-generation neurorehabilitation therapies and pave the way for broader clinical applications aimed at improving quality of life for patients with severe neurological disabilities.

FAQs on China’s Commercial BCI Implant

What is the NEO Brain-Computer Interface System?

The NEO BCI System is a commercially approved device developed by NeuraClear Medical Technology that captures neural signals and converts them into commands to support movement and rehabilitation in patients with paralysis.

How is the NEO BCI different from other brain implants?

It uses an extradural design, placing electrodes on the surface of the brain rather than penetrating brain tissue, which may lower surgical risk while still enabling high-quality signal capture.

Where was the world’s first commercial BCI implant performed?

The procedure was performed at Huashan Hospital, affiliated with Fudan University in Shanghai, China, on July 13.